Anticoagulant factor concentrates in disseminated intravascular coagulation: rationale for use and clinical experience.

Abstract

Natural inhibitors of coagulation, in other words, antithrombin (AT), the protein C system, and tissue factor pathway inhibitor (TFPI), play an important role in controlling the activation of coagulation during disseminated intravascular coagulation (DIC). Furthermore, they may not only influence coagulation but also attenuate inflammatory responses during sepsis. Low circulating levels of AT and protein C have been associated with poor outcome. Replacement therapy with AT, activated protein C (APC), and TFPI has been shown to attenuate thrombin generation and to reduce mortality in experimental sepsis models. Experience with AT and APC in patients is promising. Data from large phase III trials of AT and APC as treatment of patients with severe sepsis will soon be available. Recombinant TFPI is currently in phase II clinical trials for severe sepsis.

• Authors: E de Jonge, T van der Poll, J Kesecioglu, M Levi
• Journal: Seminars in thrombosis and hemostasis (Semin Thromb Hemost) Vol. 27 Issue 6 Pg. 667-74 (Dec 2001) ISSN: 0094-6176 [Print] United States
• PMID: 11740690 (Publication Type: Journal Article, Review)

Chemical References

• Antithrombins
• Lipoproteins
• Protein C
• lipoprotein-associated coagulation inhibitor

Topics

• Antithrombins (metabolism, therapeutic use)
• Blood Coagulation
• Clinical Trials as Topic
• Disseminated Intravascular Coagulation (blood, drug therapy, etiology)
• Humans
• Lipoproteins (blood, therapeutic use)
• Protein C (metabolism, therapeutic use)
• Sepsis (blood, complications, drug therapy)